"LA JOLLA, California â€” "If we're going to have this genomics revolution, it's going to be driven by the consumer," Anne Wojcicki, chief executive office and cofounder of 23andMe, said here at the Future of Genomic Medicine IX.
DOSAGE AND ADMINISTRATION
Administer ABLAVAR as an intravenous bolus injection, manually or by power injection, at a dose of 0.12 mL/kg body weight (0.03 mmol/kg) over a period of time up to 30 seconds followed by a 25-30 mL normal saline flush. (See Table 1 for weight-adjusted dose volumes).
TABLE 1: Weight-Adjusted
Volumes for the 0.03 mmol/kg Dose
|Body Weight||Volume Milliliters (mL)|
|Kilograms (kg)||Pounds (lb)|
Inspect the ABLAVAR vial visually for particulate matter and discoloration prior to administration. Do not use the solution if it is discolored or particulate matter is present.
ABLAVAR is intended for single use only and should be used immediately upon opening. Discard any unused portion of the ABLAVAR vial.
Do not mix intravenous medications or parenteral nutrition solutions with ABLAVAR. Do not administer any other medications in the same intravenous line simultaneously with ABLAVAR.
ABLAVAR imaging is completed in two stages: the dynamic imaging stage and the steady-state imaging stage. Both stages are essential for adequate evaluation of the arterial system, and dynamic imaging always precedes steady-state imaging. During interpretation of the steady-state images, ABLAVAR within the venous system may limit or confound the detection of arterial lesions.
To assess the initial distribution of ABLAVAR within the arterial system, begin dynamic imaging immediately upon injection. Begin steady state imaging after dynamic imaging has been completed, generally 5 to 7 minutes following ABLAVAR administration. At this time point, ABLAVAR is generally distributed throughout the blood. In clinical trials, steady-state imaging was completed within approximately one hour following ABLAVAR injection.
Dosage Forms And Strengths
ABLAVAR is a sterile solution for intravenous injection containing 244 mg/mL (0.25 mmol/mL) gadofosveset trisodium [see HOW SUPPLIED/Storage and Handling]
Storage And Handling
ABLAVAR Injection is a sterile, clear, colorless to pale yellow solution containing 244 mg/mL (0.25 mmol/mL) of gadofosveset trisodium in rubber-stoppered glass vials with an aluminum seal. ABLAVAR Injection is supplied as follows:
NDC 11994-012-01 - 10 mL fills in 10 mL single use vials
packages of 10 vials
NDC 11994-012-02 - 15 mL fills in 20 mL single use vials in packages of 10 vials
Store ABLAVAR Injection up to 25°C (77°F: excursions permitted to 15 to 30°C [59 to 86°F]). Protect from light and freezing.
Distributed by Lantheus Medical Imaging, Inc., 331 Treble Cove Road, North Billerica, MA 01862, United States. Revised: August 2013This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 8/23/2013
Additional Ablavar Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.